Skip to main content
Clinical Trials/NCT03822104
NCT03822104
Completed
Not Applicable

Bovine Colostrum to Fortify Human Milk for Preterm Infants: A Randomized, Controlled Trial

Per Torp Sangild2 sites in 1 country139 target enrollmentMay 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Feeding Intolerance
Sponsor
Per Torp Sangild
Enrollment
139
Locations
2
Primary Endpoint
Incidence of feeding intolerance
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Very preterm infants (<32 weeks gestation) show the immaturity of organs and have high nutrient requirements for growth and development. In the first weeks, they have difficulties tolerating enteral nutrition (EN) and are often given supplemental parenteral nutrition (PN). A fast transition to full EN is important to improve gut maturation and reduce the high risk of late-onset sepsis (LOS), related to their immature immunity in gut and blood. Conversely, too fast increase of EN predisposes to feeding intolerance and necrotizing enterocolitis (NEC). Further, human milk feeding is not sufficient to support nutrient requirements for growth of very preterm infants. Thus, it remains a difficult task to optimize EN transition, achieve adequate nutrient intake and growth, and minimize NEC and LOS in the postnatal period of very preterm infants. Mother´s own milk (MM) is considered the best source of EN for very preterm infants and pasteurized human donor milk (DM) is the second choice if MM is absent or not sufficient. The recommended protein intake is 4-4.5 g/kg/d for very low birth infants when the target is a postnatal growth similar to intrauterine growth rates. This amount of protein cannot be met by feeding only MM or DM. Thus, it is common practice to enrich human milk with human milk fortifiers (HMFs, based on ingredients used in infant formulas) to increase growth, bone mineralization and neurodevelopment, starting from 7-14 d after birth and 80-160 ml/kg feeding volume per day. Bovine colostrum (BC) is the first milk from cows after parturition and is rich in protein (80-150 g/L) and bioactive components. These components may improve gut maturation, NEC protection, and nutrient assimilation, even across species. Studies in preterm pigs show that feeding BC alone, or DM fortified with BC, improves growth, gut maturation, and NEC resistance during the first 1-2 weeks, relative to DM, or DM fortified with conventional HMFs. On this background, the investigators hypothesize that BC, used as a fortifier for MM or DM, can reduce feeding intolerance than conventional fortifiers.

Detailed Description

Objectives 1. To test if fortification of human milk with BC reduces feeding intolerance compared with currently used HMF. 2. To verify the safety and tolerability of BC fortification and to monitor the rates of growth, NEC and sepsis, as investigated in a parallel trial in Denmark Trial design This study is a dual-center, non-blinded, two-armed, randomized, controlled trial. Participants Parents to eligible very preterm infants admitted to the Neonatal Intensive Care Units (NICU) at Nanshan People's Hospital (NAN) and Baoan Maternal and Children's Hospital in Shenzhen, China will be asked for participation. Sample size 68 infants per group, 136 in total Data type Clinical data A parallel trial on BC used as human milk fortifier is conducting in Denmark (NCT03537365)

Registry
clinicaltrials.gov
Start Date
May 1, 2019
End Date
July 8, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Per Torp Sangild
Responsible Party
Sponsor Investigator
Principal Investigator

Per Torp Sangild

Professor

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • Very preterm infants born between gestational age 26 + 0 and 30 + 6 weeks (from the first day of the mother's last menstrual period and/or based on fetal ultrasound)
  • DM is given at the unit when MM is absent (or insufficient in amount)
  • Infants judged by the attending physician to be in need of nutrient fortification, as added in the form of HMF to MM and/or DM
  • Signed parental consent

Exclusion Criteria

  • Major congenital anomalies and birth defects
  • Infants who have had gastrointestinal surgery prior to randomization
  • Infants who have received IF prior to randomization

Outcomes

Primary Outcomes

Incidence of feeding intolerance

Time Frame: From start of intervention until the infants reach PMA 35+6 weeks or are not in need of fortification due to sufficient growth, whichever comes first

Number of infants in each group diagnosed with feeding intolerance for at least once. Feeding intolerance is defined as any pause of fortification or withhold of enteral feeding.

Secondary Outcomes

  • Time to reach full enteral feeding(From birth to hospital discharge, or up to 14 weeks)
  • Days on parenteral nutrition(From birth to hospital discharge, or up to 14 weeks)
  • Length of hospital stay(From birth to hospital discharge, or up to 14 weeks)
  • Body weight(Measured weekly from the start of intervention until hospital discharge, or up to 14 weeks)
  • Body length(Measured weekly from the start of intervention until hospital discharge, or up to 14 weeks)
  • Head circumference(Measured weekly from the start of intervention until hospital discharge, or up to 14 weeks)
  • Incidence of necrotizing entercolitis (NEC)(From the start of intervention to hospital discharge, or up to 14 weeks)
  • Incidence of late-onset sepsis (LOS)(From the start of intervention to hospital discharge, or up to 14 weeks)

Study Sites (2)

Loading locations...

Similar Trials